GlaxoSmithKline Pharmaceuticals reports Q1 FY25 PAT at Rs. 182 Cr

Strong topline growth driven by solid performance across key brands.

Lupin receives approval from USFDA for Emtricitabine and Tenofovir Alafenamide Tablets

This product will be manufactured at Lupin’s Nagpur facility in India and will be supplied to low and middle-income countries

Strides Pharma posts Q1 FY25 PAT at Rs. 68.3 Cr

The revenue for the Q1FY25 came in at Rs 1,085.7 crore, up 16.6 per cent YoY

Bayer submits NDA to USFDA for elinzanetant for the treatment of VMS associated with menopause

The New Drug Application (NDA) includes data from the Phase III studies OASIS 1, 2 and 3 - showing elinzanetant significantly reduced the frequency and severity of moderate to severe vasomotor symptoms over 12 weeks compared to placebo

Barentz acquires Anshul Life Sciences to strengthen India portfolio

The acquisition will further strengthen Barentz’ position in India creating a leading life science distribution platform

Fischer MVL and Bio Angle Vacs partner to launch livestock and aquaculture vaccines to India

BAV has revolutionized the animal vaccination industry with its ground-breaking delivery methods that prioritize quality, safety, and efficacy

GSK’s RSV vaccine ‘Arexvy’ receives positive European Medicines Agency’s CHMP opinion for adults aged 50-59

Decision on EU marketing authorisation for this population expected by September 2024

Dr. Reddy's receives positive CHMP opinion from EMA for its proposed Rituximab biosimilar

Dr. Reddy's had previously received the EU GMP certificate for its Rituximab drug substance

Aarti Drugs posts Q1 FY25 PAT lower at Rs. 33.3 Cr

Dr Reddys Laboratories posts Q1 FY25 consolidated PAT at Rs. 1,392 Cr

Dr. Reddy's Laboratories has reported total income of Rs. 7,672.7 crores during the period ended June 30, 2024